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Abstract
Background: This study was performed in order to determine whether monocyte in vitro function
is associated with presence, stage and prognosis of head and neck squamous cell carcinoma
(HNSCC) disease.
Methods: Prospective study describing outcome, after at least five years observation, of patients
treated for HNSCC disease in relation to their monocyte function. Sixty-five patients with newly
diagnosed HNSCC and eighteen control patients were studied. Monocyte responsiveness was
assessed by measuring levels of monocyte in vitro interleukin (IL)-6 and monocyte chemotactic
peptide (MCP)-1 secretion after 24 hours of endotoxin stimulation in cultures supplied either with
20% autologous serum (AS) or serum free medium (SFM). Survival, and if relevant, cause of death,
was determined at least 5 years following primary diagnosis.
Results: All patients, as a group, had higher in vitro monocyte responsiveness in terms of IL-6 (AS)
(t = 2.03; p < 0.05) and MCP-1 (SFM) (t = 2.49; p < 0.05) compared to controls. Increased in vitro
monocyte IL-6 endotoxin responsiveness under the SFM condition was associated with decreased
survival rate (Hazard ratio (HR) = 2.27; Confidence interval (CI) = 1.05–4.88; p < 0.05). The
predictive value of monocyte responsiveness, as measured by IL-6, was also retained when adjusted
for age, gender and disease stage of patients (HR = 2.67; CI = 1.03–6.92; p < 0.05). With respect
to MCP-1, low endotoxin-stimulated responsiveness (AS), analysed by Kaplan-Meier method,
predicted decreased survival (χ = 4.0; p < 0.05).
Conclusion: In HNSCC patients, changed monocyte in vitro response to endotoxin, as measured
by increased IL-6 (SFM) and decreased MCP-1 (AS) responsiveness, are negative prognostic factors.
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Background
Knowledge about the interactions between tumour cells
and the immune system has increased in the last decades.
Yet, many basic issues concerning tumour immunology
remain unanswered. An intriguing question is why the
immune system, capable of eliminating malignant cells
under experimental conditions, fails to eliminate tumour
cells in patients with progressive cancer disease. Thus, it
remains relevant to study functional changes in various
immune cells during cancer disease [1,2].
Head and Neck squamous cell carcinoma (HNSCC) is one
example of diseases where functional changes in immune
cells have been demonstrated [3,4]. Alterations in
immune cell functions in HNSCC patients are shown to
be both directly disease dependent as well as indirectly
related to disease as, e.g., when correlating to impaired
general status of patients [5]. Furthermore, it has been
shown that in vitro-stimulated lymphocyte proliferation,
as well as in vivo expression of lymphocyte activation
epitopes, may be associated with prognosis in HNSCC
patients [6,7].
Mononuclear phagocytes (MNPs) are also determined to
be functionally changed in patients with HNSCC [8].
Monocytes and macrophages may be separated into type-
I and type-II cells according to their cytokine repertoire
upon activation [9]. Interleukin (IL)-6 and other pro-
inflammatory cytokines are secreted from type-I cells,
whereas chemotactic substances such as monocyte chem-
otactic peptide (MCP)-1 are secreted mainly from type-II
cells [9]. When monocytes are stimulated in co-culture
with HNSCC tumour cells, high levels of both IL-6 and
MCP-1 can be detected in supernatants [10].
IL-6 is a pluripotent cytokine with mostly stimulatory
functions. IL-6 may, e.g., act as an autocrine or paracrine
growth factor, but also as an anti-apoptotic agent on can-
cer cells, as is the case in oral cancer [11-13]. MCP-1 was
originally determined to recruit macrophages into malig-
nant lesions [14]. MCP-1 receptor expression on tumour
cells may be important in the context of tumour cell pro-
liferation and invasion, e.g., in prostate cancer [15].
An increased influx of tumour-associated macrophages
(TAMs) in HNSCC tumours is mirrored by a worsened
prognosis, but so far no association between monocyte
function and survival of HNSCC patients has been pub-
lished [16]. We have in a previous study observed a corre-
lation between monocyte and TAM IL-6 secretion in
HNSCC, suggesting that monocyte function indeed
reflects TAM function in HNSCC patients [10]. We there-
fore suggest that monocyte function may be related to
prognosis in HNSCC patients. The aim of the present
investigation was to study this hypothesis.
Monocyte function may be assessed by measuring
cytokine secretion after in vitro stimulation of purified
monocytes with endotoxin. We have studied whether
monocyte function in HNSCC patients, as measured by in
vitro  endotoxin-stimulated monocyte IL-6 and MCP-1
secretion, was different from monocyte function in con-
trol patients and dependent on stage of HNSCC disease as
well as prognosis.
Methods
Patients and controls
The study comprised patients hospitalised at the Depart-
ment of Otolaryngology and Head & Neck Surgery,
Haukeland University Hospital, Bergen, Norway. Patients
had either squamous cell carcinoma (SCC) (N = 65) or
benign diseases of the head and neck (HN) (N = 18).
Patients with autoimmune disease or patients on corticos-
teroid medications were excluded from the study. The
study was approved by the Regional Committee for Med-
ical Ethics. Each patient gave written consent before par-
ticipating in the study. Primary sites of carcinomas were:
oral cavity (28), pharynx (22), larynx (13), maxilla (1)
and unknown primary (1). TNM stages of patients are
shown in Table 1. The diagnoses of the patients with
benign disease were: dysplastic lesions in the oral cavity or
larynx (8), benign tumours in the larynx or middle ear
Table 1: TNM stages of cancer patients evaluated for in vitro monocyte function. (Figures represent the final cTNM score of patients 
before treatment or pTNM scores based on histology from surgery, if such information was present)
N stage
0123 S u m
T stage is 2 2
11 0 6 31 9
21 22 4 11 9
3524 1 1
4833 1 4
S u m 3 771 746 5
is = in situBMC Cancer 2008, 8:34 http://www.biomedcentral.com/1471-2407/8/34
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(3), obstructive sleep apnoea (3), benign oesophageal
conditions like stenosis or diverticulum (3) as well as tym-
panic membrane defect (1). Variables such as age, tobacco
smoking and alcohol consumption are known to affect
monocyte function [17-19]. In order to evaluate the effect
of malignant disease per se on immune function, healthy
controls, matching cancer patients to these possible con-
founding variables, were selected. Ages of HNSCC
patients (62.2 ± 1.3) and controls (64.4 ± 2.5) were simi-
lar. Neither tobacco smoking (33.8 ± 2.5 versus 29.8 ± 5.1
years) nor alcohol consumption history (2.3 ± 0.16 versus
2.1 ± 0.13) differed significantly between the two groups.
After at least 5 years post-inclusion, survival was deter-
mined from the Norwegian population registry and cause
of death from a continuous follow-up registration of
HNSCC patients at our department. We found that 30 of
the 65 cancer patients were still alive, 27 had succumbed
from HNSCC disease and eight from other causes.
Alcohol consumption assessment
Each patient was interviewed at time of inclusion in the
study in order to assess smoking and alcohol habits. His-
tory of alcohol consumption was scored as follows [20]:
1, no alcohol consumed; 2, modest alcohol consumption
(less than once per week); 3, middle level alcohol con-
sumption (1–2 times weekly); 4, alcohol consumed twice
weekly; 5, alcohol consumed more than twice weekly.
Monocyte preparation
Patients were included in the study upon their arrival to
the department before any treatment started. All blood
samples were drawn at 7.30 a.m. as a bedside procedure
and each patient was asked to stay in bed until the blood
was drawn. Monocytes were isolated from blood by gradi-
ent centrifugation followed by adherence to plastic as pre-
viously described. [8] In short, peripheral blood
mononuclear cells (PBMC) were separated by gradient
centrifugation with Lymphoprep® (Nycomed, Oslo, Nor-
way) as density gradient medium. The PBMC yield of 8.5
ml blood was allocated to a 24-well plate (Nunc A/S,
Roskilde, Denmark) with RPMI-1640 (BioWhittaker) sup-
plemented with amphotericin B (2.5 μg/ml) and glucose
(both Sigma), HEPES, L-glutamine (2 mM), penicillin
(100 IU/ml), streptomycin (100 μg/ml), sodium bicarbo-
nate, sodium pyruvate (all from BioWhittaker) and 20%
autologous serum (AS) to a total volume of 0.5 ml/well.
After 40 minutes pre-incubation, adherent monocytes
were purified by washing, and then cultured in complete
RPMI (BioWhittaker)/20% AS with 0.5 ml/well. This
method yields more than 95% monocytes positive by
non-specific esterase stain with more than 95% viable
cells as tested by tryphan blue stain.
Culture conditions and stimulation
After monocytes were isolated from each donor, cells were
without delay further cultured in 0.5 ml/well, either sup-
plied with 20% (AS) or with serum free medium
(SFM)(UltraCulture, BioWhittaker). Stimulation was pro-
vided for 24 hours by 1 μg/ml lipopolysaccharide (LPS)
derived from Escherichia coli (Sigma, St. Louis, Mo., USA)
before sample collection. Cultures without LPS as stimu-
lant were used as background control conditions.
IL-6 and MCP-1 analysis
The contents of IL-6 and MCP-1 analysis in supernatants
were determined by enzyme-linked immunosorbant assay
kit (ELISA) manufactured by R&D Systems (R&D Systems
Europe Ltd., Abingdon, Great Britain). All procedures
were performed according to the specifications of the
manufacturer. Briefly, 96-well microtiter plates (Costar
Corning, Lowell, MA, USA) were coated overnight at
room temperature (RT) with monoclonal mouse α-
human IL-6 or monoclonal mouse α-human MCP-1 cap-
ture antibodies. Diluted samples or recombinant human
IL-6 or MCP-1 standard were added and incubated for 2 h
at RT followed by addition of biotinylated polyclonal goat
α-human IL-6 or goat α-human MCP-1. The plates were
then incubated for 20 minutes at RT with streptavidin-
conjugated horseradish peroxidase. Tetra-methyl-benzi-
dine (TMB) (Sigma) and H2O2 were used as substrate.
Absorbency values were measured at 450 nm using Soft-
max Pro version 4.0 on an Emax Precision microtiter plate
reader (Molecular Devices, Sunnyvale, CA, USA). The
lower detection level was 9 pg/ml for IL-6 and 16 pg/ml
for MCP-1. The median LPS-stimulated (stimulated –
background) IL-6 SFM and AS was 44251 (range 0 –
133014) pg/ml and 40551 (range -8273 – 149411) pg/
ml, respectively. The median LPS-stimulated MCP-1 SFM
(LPS-stimulated – background) and AS (background –
LPS-stimulated) was 7207 (range from -20025 to 66147)
pg/ml and -163 (range from -25718 to 13908) pg/ml,
respectively.
Statistical analysis
The statistical program package SPSS (Ver. 14; Inc Chi-
cago, IL, USA) was employed. Figures are given as mean ±
standard error of the mean. The groups were compared by
the student t-test. Survival analyses were performed by
Cox regression analysis or Kaplan-Meier (Log Rank (Man-
tel Cox) test) analyses. When limited versus extended dis-
ease patients were compared, the patients were
dichotomised by the median of the numeric sum of T and
N stage, i.e. the T and N integer score (TANIS) [21] Scores
between 0 and 3 were considered as limited disease and
scores between 4 and 7 as extended disease. With Kaplan-
Meier analyses, monocyte responsiveness was dichot-
omised into high or low responders by the median value,
as measured by the positive account of difference in IL-6BMC Cancer 2008, 8:34 http://www.biomedcentral.com/1471-2407/8/34
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and MCP-1 levels in monocyte cultures when stimulated
compared to not stimulated cultures. The median value
calculation was based on all included cytokine values. Sta-
tistical significance was considered if P < 0.05.
Results
Monocyte IL-6 and MCP-1 secretion in cancer patients 
compared to controls
When monocytes were cultured with AS and stimulated
with LPS, supernatant IL-6 levels in cultures from HNSCC
patients were higher compared to those from control
patients (53459 ± 4789 pg/ml versus 39165 ± 8179 pg/
ml. (t = 2.03; p < 0.05)). No significant difference could be
proven when SFM was utilised (Fig. 1A). A significantly
changed endotoxin-induced response compared to back-
ground release of MCP-1 secretion from monocytes in
cancer patients compared to controls was observed (1232
± 588 pg/ml versus -3860 ± 1958 pg/ml. (t = 2.49; p <
0.05)) when cultures were supplied with SFM, but not
with AS (Fig. 1B).
Monocyte IL-6 and MCP-1 secretion as related to disease 
stage
There were no differences in monocyte endotoxin
response, as measured by increased IL-6 secretion (Fig.
2A) or decreased MCP-1 secretion (Fig. 2B), when mono-
cyte cultures from HNSCC patients with extended (TANIS
= 4–7) tumour burden were compared to patients with
limited (TANIS = 0–3) tumour burden. This held true
both with autologous and serum- free medium.
Prognostic value of monocyte function
With all patients included, endotoxin-stimulated mono-
cyte IL-6 secretion was found to be significantly higher in
monocyte cultures from patients that had died after 5
years follow-up compared to that of living patients, both
at SFM (t = 2.03; p < 0.05) and AS (t = 2.17; p < 0.05) con-
ditions (Fig. 3A). Endotoxin-induced compared to back-
ground monocyte MCP-1 secretion was not different in
patients alive after five years compared to those that had
Levels of IL-6 and MCP-1 in the supernatants of 24 hours, in  vitro endotoxin (1 μg/ml LPS)- stimulated purified monocytes  from cancer patients with low (T- + N-stage < 3) (limited)  versus high (T- + N-stage > 3) (extended) tumour burden Figure 2
Levels of IL-6 and MCP-1 in the supernatants of 24 hours, in 
vitro endotoxin (1 μg/ml LPS)- stimulated purified monocytes 
from cancer patients with low (T- + N-stage < 3) (limited) 
versus high (T- + N-stage > 3) (extended) tumour burden. 
Cultures were either supplied with 20% autologous serum 
(AS) or serum free medium (SFM). The bars represent means 
± SEM of supernatant levels. (LPS-stimulated – baseline lev-
els: IL-6 SFM/AS & MCP-1 SFM. Baseline – LPS-stimulated: 
MCP-1 AS).
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died during the same period at any of the two culture con-
ditions (Fig. 3B).
Including HNSCC patients only, Kaplan-Meier analysis
showed that patients with high monocyte responsiveness
to endotoxin, as measured by high IL-6 secretion (SFM),
had decreased total (Fig. 4A) (χ = 4.3; p < 0.05) as well as
disease-specific (Fig. 4B) (χ = 4.4; p < 0.05) survival com-
pared to patients with low monocyte responsiveness.
When MCP-1 values from AS conditions were analysed by
Kaplan-Meier analysis, a low responsiveness predicted
decreased total survival (χ = 4.0; p < 0.05) (Fig. 5A), and
with a trend toward the same with disease-specific sur-
vival (χ = 3.6; p = 0.06) (Fig. 5B).
With only HNSCC patients included, IL-6 secretion at
SFM predicted survival as follows: Cox regression survival
analyses, showed that LPS-stimulated monocyte IL-6
secretion, adjusted for gender and age of patients, pre-
dicted both total as well as disease-specific survival (p <
0.05) when analysed with original results (Table 2, upper
panel) and when analysed dichotomised (Hazard ratio
(HR) = 2.27; Confidence interval (CI) = 1.05–4.88; p <
0.05 and HR = 2.68; CI = 1.11–6.45;p < 0.05, respectively)
(Table 3, upper panel).
Kaplan-Meier plot survival dependent on total survival (A) or  disease-specific survival (B) according to IL-6 in vitro secre- tion from purified monocytes following 24 hours, endotoxin  (1 μg/ml LPS) stimulation dichotomised by median value to  low (hatched line) or high (continuous line) response with  serum free medium (SFM) applied (background subtracted) Figure 4
Kaplan-Meier plot survival dependent on total survival (A) or 
disease-specific survival (B) according to IL-6 in vitro secre-
tion from purified monocytes following 24 hours, endotoxin 
(1 μg/ml LPS) stimulation dichotomised by median value to 
low (hatched line) or high (continuous line) response with 
serum free medium (SFM) applied (background subtracted). 
Statistics by Log Rank (Mantel Cox) test.
p<0.05
p<0.05
A
B
Levels of IL-6 and MCP-1 in the supernatants of 24 hours, in  vitro endotoxin (1 μg/ml LPS)- stimulated purified monocytes  cultures from dead versus live patients with observations at  least 5 years following inclusion Figure 3
Levels of IL-6 and MCP-1 in the supernatants of 24 hours, in 
vitro endotoxin (1 μg/ml LPS)- stimulated purified monocytes 
cultures from dead versus live patients with observations at 
least 5 years following inclusion. Cultures were either sup-
plied with autologous serum (AS) or serum free medium 
(SFM). The bars represent means ± SEM of supernatant level. 
(LPS-stimulated – baseline levels: IL-6 SFM/AS & MCP-1 SFM. 
Baseline – LPS-stimulated: MCP-1 AS). Statistics by students' 
t-test.
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When adjusting for age, gender as well as TNM stage, a
prediction for disease-specific survival was determined
when IL-6 levels were analysed dichotomised (HR = 2.44;
CI = 1.01–5.92; p < 0.05) (Table 3, lower panel). A trend
towards disease-specific survival prediction was also
observed when IL-6 levels were analysed with original
results (p = 0.066), (Table 2, lower panel). Likewise, a
trend towards survival prediction was observed as to total
survival when IL-6 levels were analysed dichotomised
(HR = 2.08; CI = 0.97–4.48; p = 0.061), (Table 3, lower
panel). Furthermore, when monocyte LPS-stimulated IL-6
secretion values were analysed dichotomised, survival
prediction was also present with disease-specific survival
(HR = 2.62; CI = 1.14–6.08; p < 0.05) and total survival
(HR = 3.10; CI = 1.15–8.39; p < 0.05), when adjusted for
gender and age as well as serum albumin and erythrocyte
sedimentation rate (ESR) values of patients (analyses not
shown). When adjustment for TNM stage was addition-
ally introduced, predictions were still observed, both as
measured by disease-specific survival (HR = 2.31; CI =
1.02–5.21; p < 0.05) and total survival (HR = 2.67; CI =
1.03–6.92; p < 0.05) (analyses not shown).
When dichotomised MCP-1 values were introduced in a
Cox regression survival analysis, adjusted for age and gen-
der of patients, we determined a trend as to prediction of
total survival at the AS condition (HR = 1.99; CI = 0.95–
4.18; p = 0.069) (Table 4, upper panel). Adjusting for age,
gender as well as TNM stage of patients, we determined
prediction of survival at SFM conditions (HR = 2.42; CI =
1.03–5.69; p < 0.05), (Table 4, lower panel).
Discussion
In this study, we have examined monocyte responsive-
ness, as measured by in vitro endotoxin responsiveness, by
monocyte IL-6 and MCP-1 secretion. Monocyte respon-
siveness was increased in monocytes from HNSCC
patients compared to control conditions. On the other
hand, no difference in monocyte responsiveness was
found when HNSCC patients with limited versus
extended disease were compared. Patients with high
monocyte responsiveness as measured by IL-6 secretion at
serum-free conditions had lower disease-specific survival
than patients with low such monocyte responsiveness.
Predictions for survival based on monocyte IL-6 secretion,
were still valid after adjusting for gender, age, TNM stage,
albumin and ESR levels. Furthermore, we determined to
some extent that MCP-1 secretion following endotoxin
stimulation was related to prognosis. We have, however,
determined a much more thorough correlation to progno-
sis with IL-6 levels than with MCP-1 levels. We therefore
suggest that MCP-1 level survival prediction should be
more closely studied before any firm conclusions can be
drawn. Our observations are in line with results from a
recent study by Clinchy and co-workers showing that
increased IL-6 secretion, in short-duration in vitro cultures
of peripheral blood mononuclear cells stimulated with
LPS, was associated with impaired prognosis in patients
radically operated for colon cancer [22]. Monocyte IL-6
and MCP-1 secreted from endotoxin- stimulated mono-
Kaplan-Meier plot survival dependent on total survival (A) or  disease-specific survival (B) according to MCP-1 in vitro secre- tion of purified monocytes following 24 hours endotoxin (1  μg/ml LPS) stimulation dichotomised by median value to low  (hatched line) or high (continuous line) responsiveness with  20% autologous serum (AS) added to the medium applied  (background – LPS stimulated response) Figure 5
Kaplan-Meier plot survival dependent on total survival (A) or 
disease-specific survival (B) according to MCP-1 in vitro secre-
tion of purified monocytes following 24 hours endotoxin (1 
μg/ml LPS) stimulation dichotomised by median value to low 
(hatched line) or high (continuous line) responsiveness with 
20% autologous serum (AS) added to the medium applied 
(background – LPS stimulated response). Statistics by Log 
Rank (Mantel Cox) test.
p<0.05
p=0.06
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cytes may be linked to an altered inflammatory state as
previously shown in HNSCC patients. Examples are
increased ESR, lowered albumin values in serum,
increased levels of acute-phase proteins and pro-inflam-
matory cytokines [23,24]. This has been studied by add-
ing serum albumin and ESR level information to the Cox
regression analyses. We determined only minor explana-
tory power upon adjusting for ESR and albumin in serum.
On the contrary, to some extent the IL-6 secretion level,
serum albumin levels and ESR independently predicted
survival.
We found no association between tumour burden and
monocyte function in the present study. This argues
against monocyte function being linearly regulated by
HNSCC disease-related factors, such as cytokines secreted
from tumour-associated cells. The findings in the present
study indicate that monocyte changes are generally
present in malignant disease and to a lesser extent influ-
enced by tumour burden.
There is evidence to claim that nuclear factor -κB (NF-κB),
which regulates expression of multiple genes in cells, may
act as a link between infection, inflammation and carcin-
ogens in development of cancer [25]. The pro-inflamma-
tory cytokine IL-6 may have an important role in this
process by serving as an anti-apoptotic agent through acti-
vation of NF-κB [26]. Our present finding, that increased
IL-6 secretion from monocytes predicts prognosis of
HNSCC disease, further supports the notion that inflam-
matory responses may cause both initiation and progres-
sion of neoplastic growth [12].
Another effect of IL-6 is its increased promotion of mono-
cyte differentiation towards macrophages at the expense
of dendritic cell (DC) differentiation [27]. Monocytes are
recruited by chemokine gradients to migrate from circula-
tion into tumour tissues where a further differentiation to
TAMs or DCs takes place under the regulation of environ-
mental signals of such as IL-6 [27]. There is currently an
increasing agreement that TAMs in carcinoma disease may
Table 3: Multivariate Cox Regression Survival Analysis with Dichotomised Scored Monocyte IL-6 Secretion (serum-free medium) 
Adjusted for Gender and Age (upper panel), or adjusted for Gender, Age and TN stage (lower panel) of HNSCC Patients
Total survival Disease-specific survival
HR 95% CI (HR) P value HR 95% CI (HR) P value
Gender 0.52 0.18–1.52 0.236 0.35 0.10–1.31 0.119
Age 1.07 1.02–1.11 0.002 1.08 1.03–1.28 0.002
IL-6 2.27 1.05–4.88 0.036 2.68 1.11–6.45 0.028
Gender 0.54 0.20–1.50 0.237 0.40 0.11–1.41 0.153
Age 1.06 1.02–1.11 0.008 1.06 1.01–1.11 0.025
T stage 1.64 1.18–2.29 0.003 1.89 1.29–2.79 0.001
N stage 1.55 1.06–2.28 0.025 1.61 1.03–2.51 0.035
IL-6 2.08 0.97–4.48 0.061 2.44 1.01–5.92 0.049
HR = Hazard ratio 95% CI(HR) = 95% confidence interval for HR
Table 2: Multivariate Cox Regression Survival Analysis with Monocyte IL-6 secretion in pg/ml (serum-free medium) Adjusted for Age, 
Gender and TN stage of HNSCC Patients
Total survival Disease-specific survival
BS E P value B SE P value
Gender -.365 .531 .492 -.707 .654 .280
Age .062 .021 .003 .068 .024 .004
IL-6 .000 .000 .029 .000 .000 .024
Gender -.451 .510 0.779 -.726 .632 0.250
Age .057 .022 0.022 .055 .025 0.028
T stage .496 .167 0.003 .647 .195 0.001
N stage .384 .199 0.054 .420 .230 0.068
IL-6 .000 .000 0.110 .000 .000 0.066
B = regression coefficient, SE = Standard error of BBMC Cancer 2008, 8:34 http://www.biomedcentral.com/1471-2407/8/34
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support tumour growth by virtue of their differentiation
into type II macrophages [28]. Compared to TAMs, DCs
apparently have a contrary effect within HNSCC tumours,
whereby a high number of DCs correlates with better
prognosis [29,30]. Furthermore, it has previously been
demonstrated that monocytes maintain IL-6 secretion
throughout their differentiation to macrophages when
continuously stimulated with HNSCC tumour spheroids
in vitro [31]. We therefore suggest that the malignancy
potential of HNSCC relies to some extent on IL-6 stimula-
tion by TAMs.
MCP-1 regulates TAM influx into tumours and may also
be secreted by TAMs [10]. It is therefore possible that
MCP-1 mediates a self-enhancing effect driven by TAMs
within tumours. Increased expression of MCP-1 in squa-
mous cell carcinomas of the oesophagus has been associ-
ated with increased influx of TAMs and an impaired
prognosis [32]. In vitro experiments indicate that these
findings may be relevant for HNSCC as well [16]. To what
extent the shown lowered monocyte MCP-1 responsive-
ness association to increased prognosis can be linked to
TAM influx in HNSCC tumours needs to be further eluci-
dated.
The observations in the present study add weight to the
arguments that activated MNPs may in fact increase rather
than reduce tumour cell aggressiveness in HNSCC. Still,
TAMs may in some cytokine environments have tumour
suppressive potentials, which probably explains observa-
tions of improved prognosis associated with high num-
bers of TAMs in some other types of malignancies [33,34].
The observed reductions in HNSCC tumour mass when
injected with biological response modifiers such as OK-
432, may be in part be explained by such macrophage
activation [35].
Previously, it has been shown that monocytes in HNSCC
patients compared to control patients are primed for an
increased sensitivity to endotoxin stimulation as meas-
ured by cytokine secretion [8]. The present study confirms
these observations and further shows that monocyte func-
tion actually may provide information as to prognosis of
HNSCC disease. We have previously determined in
another patient sample that IL-6 secretion from mono-
cytes did not predict survival. It should, however, be noted
that patients with more affected capability, as measured
by Karnofsky scores below 75, were included in the
present study as opposed to a previous study [20]. Fur-
thermore, when both of these samples were combined,
prediction relying on monocyte IL-6 secretion was similar
to this study (manuscript in preparation).
Both alcohol consumption and tobacco smoking are
expected to be higher among HNSCC patients than in the
general population because consumption of these sub-
stances has been linked to an increased risk of HNSCC
[36]. Smoking and alcohol use may influence monocyte
function [18,19,37]. In the present investigation, how-
ever, differences between HNSCC patients and control
patients, as well as differences between the two HNSCC
patient groups, and prognosis were present still after
adjusting for tobacco and alcohol consumption. The
observed changed monocyte function in HNSCC patients
can therefore not be explained by alcohol consumption or
tobacco smoking.
Monocyte sensitivity to endotoxin reflects prognosis
when adjusted for TNM stage. Therefore it may be possi-
ble to identify patients having a better prognosis despite
extended HNSCC disease. This might justify the use of a
more extensive therapy regime in some selected patients
with otherwise very extended TNM stage.
Table 4: Multivariate Cox Regression Total Survival Analysis with Dichotomised Scored Monocyte MCP-1 Secretion adjusted for 
Gender, Age, and TNM stage of HNSCC Patients
Serum-free medium Autologous serum medium
HR 95% CI (HR) P value HR 95% CI (HR) P value
Gender 0.73 0.26–2.03 0.546 0.61 0.24–1.59 0.311
Age 1.05 1.01–1.09 0.014 1.04 1.00–1.08 0.027
MCP-1 1.20 0.58–2.48 0.617 1.99 0.95–4.18 0.069
Gender 0.41 0.12–1.41 0.166 0.55 0.22–1.41 0.216
Age 1.05 1.00–1.10 0.043 1.04 1.00–1.09 0.036
T stage 2.01 1.41–2.87 0.000 1.57 1.12–2.20 0.008
N stage 1.84 1.16–2.90 0.009 1.50 1.02–2.22 0.041
MCP-1 2.42 1.03–5.69 0.043 1.28 0.57–2.89 0.554
HR = Hazard ratio 95% CI(HR) = 95% confidence interval for HRBMC Cancer 2008, 8:34 http://www.biomedcentral.com/1471-2407/8/34
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Observations from in vitro studies suggest that IL-6 pro-
motes cell proliferation and prevents apoptosis in HNSCC
cell lines via activation of signal-transducers-and-activa-
tors-of-transcription-3 (STAT3) via a common β-chain of
the epidermal growth factor receptor (EGFR) [38]. STAT3
plays a critical role in the oncogenesis of several malig-
nancies and has been shown to be activated in tumour tis-
sue and in normal mucosa of HNSCC patients [39]. The
activation of STAT3 is, however, shown to be complexly
regulated via different kinases and supressors of cytokine
signalling genes, which may explain the failure of treat-
ment protocols based on EGFR- tyrosine kinase inhibitors
[40]. Lee and co-workers therefore suggest that multiple
pathways to stimulate STAT3 should be targeted in
patients with HNSCC in order to achieve maximal clinical
efficacy [40]. Thus, one possible additional therapeutic
pathway could be an inhibition of the IL-6 stimulation of
the tumour cells through therapeutic use of anti-IL-6 anti-
bodies [41].
Conclusion
We have shown that monocyte function, as measured by
endotoxin-induced in vitro monocyte regulation of IL-6
secretion at AS conditions was higher, whereas, MCP-1
secretion at SFM condition was less inhibited in HNSCC
patients compared to controls. Monocyte function also
predicted outcome in HNSCC patients. A high LPS-
induced monocyte IL-6 responsiveness, and to some
extent decreased MCP-1 responsiveness, predicted wors-
ened prognosis independent of TNM stage. Thus, mono-
cyte function is directly associated with the biology of
HNSCC. We suggest that future studies should take into
account the possible use of α-IL-6 antibodies as an adju-
vant treatment for HNSCC disease.
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